Register or Sign in to Save this opportunity, or Send an Inquiry.
Cartisorb - Glucosamine
Bioiberica Spain flag Spain
Abstract ID:
Cartisorb® is indicated for the symptomatic treatment of osteoarthritis.
Send an Inquiry
RE:
Participants
You
Introduction/Background
Glucosamine is an endogenous substance, a normal constituent of the polysaccharide chain of cartilage matrix and synovial fluid glycosaminoglycans. In vitro and in vivo studies have shown that glucosamine stimulates the physiological synthesis of glycosaminoglycans and proteoglycans through the chondrocytes and of hyaluronic acid through synoviocytes.

Description of Technology
• Cartisorb capsules 625 mg Glucosamine: The only two-capsule a day glucosamine based pharmaceutical product.

  ○ Improved pharmaceutical presentations for a better compliance

  ○ Authorized and available for licensing out in UK. CTD Dossier ready for registration

• Cartisorb sachets contain 1.5000 mg glucosamine sulfate as 1,884 mg of glucosamine sulfate sodium chloride, equivalent to 1,178 mg of glucosamine.

  ○ Lemon flavor: Improving patients compliance and acceptance

  ○ CTD Dossier ready for registration
Type of Business Relationship Sought
Available for out-licensing
FEATURED
Last Updated Oct 2017
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION

Opportunity Contact